Venus Remedies has joined the United Nations Global Compact (UNGC), aligning its operations with the initiative’s Ten Principles covering human rights, labour, environment, and anti-corruption. The company will now publish an annual Communication on Progress (CoP) to report on its adherence to these principles and overall sustainability performance.
As part of this affiliation, Venus Remedies has extended its Environmental, Social, and Governance (ESG) framework across international operations. The company has secured ISO 14064-1 certification for greenhouse gas emissions reporting, enhancing transparency in its environmental performance and carbon management.
“At Venus Remedies, we believe in advancing science with a strong sense of responsibility,” said Ms Aditi K. Chaudhary, President, International Business, Venus Remedies. “Our decision to join the United Nations Global Compact is a natural extension of our core values, where access, ethics, and excellence converge. This milestone not only enhances our global standing but also reaffirms our commitment to driving meaningful change. We view this as a deep responsibility to our global partners, the healthcare systems we support, and the shared future of our planet.”
The company’s participation in the UNGC supports its long-standing role in public health. Venus Remedies has supplied WHO-prequalified pharmaceuticals to international health agencies and secured contracts with UNICEF for ceftriaxone and with the Pan American Health Organization (PAHO) for oncology treatments. These partnerships aim to deliver essential medicines to underserved regions in Latin America, Africa, and Asia.
Venus Remedies has placed antimicrobial resistance (AMR) at the centre of its research and development strategy, aligning with Sustainable Development Goal 3 and its broader ESG-led innovation agenda. The company identifies AMR as a global sustainability issue affecting health systems, food security, and environmental stability.
The company’s pipeline includes VRP-034, a novel polymyxin B formulation that has received Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration under the GAIN (Generating Antibiotic Incentives Now) Act. This designation offers fast-track regulatory review and additional market exclusivity.
In addition to product development, Venus Remedies supports global AMR surveillance and policy. It leads initiatives such as GASAR (Global Antimicrobial Surveillance and Resistance) and the PLEA Trust, which promote antibiotic stewardship and data generation. The company also engages in collaborative efforts through the AMR Industry Alliance, the India AMR Innovation Hub, and the Vivli AMR Register.
Venus Remedies maintains regulatory approvals from EU-GMP (INFARMED), PIC/S members including Malaysia and Ukraine, SAHPRA, UNICEF, TGA, INVIMA, and WHO-GMP. It also holds ISO certifications for quality management (ISO 9001), environmental management (ISO 14001), and occupational health and safety (ISO 45001).
The company continues to collaborate with national regulators, international donors, and institutional buyers to expand access to affordable and quality-assured therapeutics worldwide.
